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Background: the purpose of this study was to perform a systematic review regarding clinical and histopathological 
characteristics, immunopathological findings, and treatment for chronic ulcerative stomatitis (CUS).
Material and Methods: articles in English, published from January 1962 up to November 2017, assessing clinical 
and immunological features, treatment, and follow-up of patientes with CUS, were retrieved from three databases 
(PubMed, Cochrane Library and SCOPUS). A manual literature search was also conducted. A total of 12 studies 
met inclusion criteria, therefore, were analyzed in this review.
Results: CUS shares similiar clinical and microscopic features to those found in oral lichen planus (OLP) and oral 
lichenoid lesions (OLL). Hence, direct immunofluorescence (DIF) is indispensable to define a final diagnosis. Due 
to the poor sample availability in the current literature, it is not possible to accurately confirm the prevalence and 
features of CUS.
Conclusion: in order to better evaluate this condition’s findings, further studies with a greater amount of similar 
immune-mediated diseases should be performed.
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Introduction
Chronic ulcerative stomatitis (CUS) is a poorly under-
stood chronic condition that causes painful, exacerbat-
ing, and remitting ulcerations, particularly in oral mu-
cous membranes (1). To the best of our knowledge, there 
are only few cases of CUS reported in the English-lan-
guage literature. Since this condition may be confounded 
with other autoimmune diseases, especially oral lichen 
planus (OLP), it is likely that many cases are misdiag-
nosed (2,3). Histopathologic findings are non-specific. 
However, suggestive features include atrophic, parake-
ratinized and stratified squamous epithelium, lichenoid 
inflammatory cell infiltrates, basal cell degeneration, and 
cytoid bodies (1). Moreover, direct immunofluorescence 
(DIF) of lesional and perilesional specimens shows the 
presence of autoantibodies with a stratified epithelial 
specific-antinuclear antibody (SES-ANA) pattern (4). 
These autoantibodies target an antigen, deltaNp63alpha, 
which is a nuclear protein normally present in the basal 
and parabasal cells of stratified squamous epithelia (5,6).
Distinctively from other immunologically mediated con-
ditions, such as OLP, mucous membrane pemphigoid, 
pemphigus vulgaris, linear IgA disease, and lichenoid 
drug reaction (6,7), CUS does not show a good response 
to corticosteroids when compared to other treatments, as 
hydroxychloroquine (2). Hence, an accurate diagnosis is 
extremely important to establish an appropriate manage-
ment (8).
Currently, no study has systematically evaluated the 
clinical and histopathological characteristics and the 
immunofluorescence pattern of CUS. Thus, the aim of 
the present study is to provide an overview of the above-
mentioned features observed in CUS. This research fol-
lowed the Preferred Reporting Items for Systematic Re-
views and Meta-Analyses (PRISMA) checklist (9). The 




The research question was based on the “PVO” strategy 
for systematic exploratory review. P stands for the pop-
ulation, context and/or problem situation, V for the vari-
ables, and O for the desirable or undesirable outcomes. 
This study aimed to answer the following focused ques-
tion: Do clinical, histopathological, and immunopatho-
logical features of CUS overlap with other autoimmune 
disorders characteristics?
Inclusion criteria for our systematic review were (i) 
studies describing clinical, histopathological, and im-
munopathological findings in oral chronic ulcerative 
stomatitis patients; (ii) cases reports, case series and 
cross-sectional studies; and (iii) articles published in 
English.
Criteria for excluding studies were (i) experimental 
analysis conducted in animals or in vitro models; (ii) re-
views articles, letters, personal opinions, book chapters, 
or conference abstracts; (iii) articles published by the 
same authors or groups with duplicate patient data; and 
(iv) studies in which patients had associated systemic 
disorders (e.g., Sjögren’s syndrome and systemic lupus 
erythematosus).
- Search strategy
Two independent examiners conducted an electronic 
search in the PubMed/MEDLINE, Cochrane Library 
and SCOPUS databases for articles published between 
January 1962 and November 2017. 
The following search terms and combinations were 
used: “oral chronic ulcerative stomatitis” and “chronic 
ulcerative stomatitis”. In addition, a handsearching was 
conducted through the journals Oral Diseases, Head & 
Neck Pathology, International Journal of Maxillofacial 
Surgery, Journal of Dental Research, and Oral Surgery, 
Oral Medicine, Oral Pathology, Oral Radiology. 
Based on the studies titles and abstracts, two indepen-
dent researchers selected and classified the articles as 
included or excluded in the review. The Mendeley Ref-
erence Manager Software® was used to delete duplicate 
articles. Data was extracted from the selected articles, 
and an independent researcher guided the development 
of this review. Studies were analyzed and discussed. 
Any possible disagreements during the process were 
solved before proceeding to the next steps.
- Data extraction and analysis
The following data was extracted from the studies: (a) 
demographic data (age, gender and ethnicity); (b) num-
ber of investigated patients; (c) detailed clinical descrip-
tions of oral lesions (oral sites, signs and symptoms); 
(d) description of histophatological characteristics; (e) 
description of immunopathological characteristics; (f) 
treatment choice, and (g) follow-up duration. The Level 
of Evidence (LoE) for each study was determined ac-
cording to the guidelines of the Oxford University Cen-




The article selection process is summarized in the flow 
diagram presented in Fig. 1. Initial electronic search 
yielded 444 articles. 108 duplicate articles were exclud-
ed, therefore, 336 papers remained in the study.
After title and abstract screening, 306 articles were 
excluded. A total of 30 articles were eligible for full-
text evaluation. Subsequently to full-text evaluation, 12 
articles were included for qualitative analysis (1,2,4,11-
19). Two studies were a cross-sectional, five were case-
series and five were case reports. Inter-examiner agree-
ment test (kappa statistic) was applied. For the PubMed/
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Medline, Cochrane Library and SCOPUS databases, as-
sessment was 100% (κ = 1). For handsearching, the test 
was also 100% (κ = 1). Characteristics of included stud-
ies and their LoE are summarized in Table 1.
Selected studies reported 32 patients with CUS. Four 
articles were excluded from the systematic review ow-
ing to the lack of sufficient details regarding clinical 
presentation, microscopic features or treatment in rela-
tion to individual subjects (3,7,8,20). Additionally, three 
patients were excluded, as they presented Sjögren’s syn-
drome (2,6) or systemic lupus erythematosus (19) as-
sociated with CUS.
- Synthesis of results
The systematic review showed that CUS affects patients 
at an average age of 57 years (range 36-81 years), with a 
strong female predilection (30 women and 2 men). The 
majority of studies have European origin; consequently, 
75% of CUS patients were white. Simultaneous oral and 
skin lesions were observed in 18.7% of the cases. In-
volvement of multiple oral sites was reported in nearly 
78% cases, mostly affecting areas that included buccal 
mucosa, tongue, and gingiva. Bilateral presentation was 
observed in four cases. The condition generally pres-
ents as a symptomatic erosive or ulcerative lesion with 
subtle white reticular striations. Nonetheless, a pure 
erosive and ulcerative stomatitis may occur. Patients 
usually suffer from varying degrees of discomfort in-
cluding pain, dry mouth, and irritation. A summary of 
the clinical findings obtained in the included studies is 
shown in Table 2.
Fig. 1: Flow diagram for study selection; 12 studies were identified 
for analysis (as adapted from the PRISMA statement).



















Jaremko et al.4 1990 Case-series 4 4/0 1B/3W 73
HE; DIF; 
IIF; SS
Hy; Ct; At; 
ATB
ND IV
Beutner et al.11 1991 Case-series 4 3/1 4W 54 DIF; IIF Hy; Ct 2 weeks IV
Church et al.12 1992 Case report 1 1/0 W 71 HE; DIF; IIF Ct 8 years IV
Lewis et al.13 1996 Case report 1 1/0 W 73 HE; DIF, IIF Hy 2½ years IV






Solomon et al.1 2003 Case-series 3 3/0 3W 54 HE; DIF; IIF Hy; Ct 2 months IV
Islam et al.2 2007 Case-series 3 3/0 3W 67 HE; DIF Hy; Ct 5 months IV
Rinaggio et al.15 2007
Cross-sec-
tional
1 1/0 ND 36 HE; DIF ND ND III b
Fourie et al.16 2011 Case report 1 1/0 ND 42 HE; DIF; IIF Hy; CyA 6 months IV
Jacyk et al.17 2012 Case report 1 1/0 W 43 HE; DIF Hy; CyA 2 months IV
Qari et al.18 2015 Case-series 10 9/1 8W/2ND 56 HE; DIF Ct 2 years IV
Alshagroud et al.19 2017
Cross-sec-
tional
2 2/0 ND 59 HE;DIF;SS ND ND III b
ND: Not documented; F: Female; M: Male; B:black; W: white; HE: Routine HE-stained; DIF: Direct immunofluorescence; IIF: Indirect im-
munofluorescence; SS: Serum studies; Hy: hydroxychloroquine; Ct: topical corticosteroid; At: topical antihistamine; ATB: topical antibiotic; 
DDS: diaminodiphenyl sulfone and CyA: Cyclosporin A.
*OxfordUniversity Center for Evidence-based Medicine levels of Evidence Working Group
Table 1: Summary of the 12 included studies characteristics.
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Light microscopic features in some CUS cases are re-
ported to be indistinguishable from OLP or to show oral 
lichenoid lesions (OLL) features, sometimes it is also 
described as a nonspecific ulcer. In our systematic re-
view, according to a set of modified World Health Orga-
nization (WHO)’s diagnostic criteria for OLP and OLF 
(21), 13 cases met the microscopic criteria of OLP, while 
17 cases displayed as OLL. In all cases, histopathologi-
cal diagnosis of CUS was reached through DIF. DIF in 
lesional and perilesional oral mucosal specimens re-
vealed a finely speckled granular pattern of IgG deposi-
tion, which is normally expressed in basal cell nuclei of 
stratified squamous epithelia. In addition, we observed 
that 18 cases (56%) showed a lichenoid fibrin deposits 
pattern. Moreover, the DIF for anti-human IgA, IgM 
and C3 were only positive in 20%, 0% and 0% cases of 
CUS, respectively. The DIF outcomes for the 32 evalu-
ated patients are summarized in Table 3.
Hydroxychloroquine was found to be the drug of choice 
in limiting the disease. Patients remained asymptomatic 
for a long time after its usage. Most reports state that in 
spite of the discontinuation of hydroxychloroquine ther-
apy, the majority of patients stayed in remission or had 
a disease-free status. Dose adjustments relative to body 
weight, severity, and extent of involvement are of great 
importance, although there is a recommended starting 
daily dose of 200 mg, to a maximum of 800 mg (2,22).
Discussion
CUS was first reported as a unique entity with excel-
lent response to hydroxychloroquine (4). This entity 
has been known as a chronic ulcerative lesion associ-
ated with a stratified epithelium-specific antinuclear 
antibody (SES-ANA) that reacts predominantly with 
the epithelium’s basal layer (4). Many groups have de-
scribed cases or series-reports of oral chronical ulcer-
ations lesions with SES-ANA immunologic pattern (1-
4,6,7,11-20). However, the small number of reports does 
not allow the establishment of the real prevalence and 
features of CUS. This is probably related to many cases 
that are actually undiagnosed. To the best of our knowl-
edge, the present systematic review is the first to assess 
the clinical, microscopic and immunological character-
istics, and therapeutic outcomes systematically.
The present results indicate that CUS is most common 
in white women in the fifth decade of life. The exclu-
sive oral cavity involvement occurred in 81.2% of the 
cases. Nevertheless, skin or other mucous membranes 
may be involved as well. The condition has been re-
ported as progressive painful erythematous gingival 
lesions, with large, tender erosions, ulcerations, and 
vesicle formation, raising a clinical suspicion of erosive 
lichen planus. Here, we show that CUS often presents as 
a symptomatic erosive or ulcerative lesion with subtle 
white reticular striae. Main symptoms include pain, dry 
Table 2: Summary of clinical findings in 32 cases.
Findings Frequency N (%) Comments
Age












Oral + Skin 6 (18,7)
No. of affected oral 
sites
One 5 (15.6)
Two or more 25 (78.1)
ND 2 (6.2)
Oral location
Buccal mucosa 23(71.9) Bilateral presenta-
tion was observed 
in four cases and 28 
were not document-





Labial mucosa 1 (3.1)












rative + Blister 1 (3.1)
ND 3 (9.4)
Symptoms
Yes 22 (68.7) Main symptoms 




SD: Standard Deviation; ND: Not documented
e702
Chronic ulcerative stomatitisMed Oral Patol Oral Cir Bucal. 2019 Nov 1;24 (6):e698-703. 
Table 3: Summary of immunofluorescence findings in 32 cases.
Nuclear reactions Basement membrane zone
Study IgG IgA IgM Pattern IgG IgA IgM Fibrin C3
Jaremko et al.4 #1 + + - Speckled - - - + -
#2 + + - Speckled - - - + -
#3 + - - Speckled - - - + -
#4 + - - Speckled - - - + -
Beutner et al.11 #5 + ND ND Speckled - ND ND ND ND
#6 + ND ND Speckled - ND ND ND ND
#7 + ND ND Speckled - ND ND ND ND
#8 + ND ND Speckled - ND ND ND ND
Church et al.12 #9 + ND ND Speckled - ND ND + ND
Lewis et al.12 #10 + ND ND Speckled - ND ND + ND
Wörle et al.14 #11 + + ND Speckled - - ND ND ND
Solomon et al.1 #12 + - - Speckled - - - ND ND
#13 + + - Speckled - - - ND ND
#14 + - - Speckled - - - ND ND
Islam et al.2 #15 + - - Speckled - - - + -
#16 + - - Speckled - - - - -
#17 + - - Speckled - - - - -
Rinaggio et al.15 #18 + - - ND - - - + ND
Fourie et al.16 #19 + + ND Speckled - - ND ND ND
Jacyk et al.17 #20 + + ND ND ND ND ND ND ND
Qari et al.18 #21 + - - Speckled ND + + + ND
#22 + - - Speckled ND + + + ND
#23 + - - Speckled ND + + + ND
#24 + - - Speckled ND + + + ND
#25 + - - Speckled ND + + + ND
#26 + - - Speckled ND + + + ND
#27 + - - Speckled ND + + + ND
#28 + - - Speckled ND + + + ND
#29 + - - Speckled ND + + + ND
#30 + - - Speckled ND + + + ND
Alshagroud et al..19 #31 + - - Speckled ND ND ND ND ND
#32 + - - Speckled ND ND ND ND ND
ND: Not documented; +: Positive; -: Negative
mouth, and irritation. Other symptoms are nervousness, 
fatigue, inability to eat, inability to drink hot or cold 
drinks, weight loss, and sleeplessness (1,2,4,11-14,16).
CUS often shares some clinical and histopathological 
features with OLP, lichenoid stomatitis, mucous mem-
brane pemphigoid, dermatitis herpetiformis, linear IgA 
disease, pemphigus vulgaris, erythema multiforme, 
pyostomatitis vegetans, and epidermolysis bullosa ac-
quisita (7). Our results showed that DIF in lesional and 
perilesional oral mucosal specimens is indispensable to 
establish the differential diagnosis of CUS. The finely 
speckled granular pattern of IgG deposition in basal cell 
nuclei of stratified squamous epithelia and a lichenoid 
fibrin deposits pattern were the most accurate and reli-
able features to address the lesion as being CUS. None-
theless, experienced laboratory technicians are manda-
tory to conduct DIF, a high cost test. Otherwise limiting 
its performance. As a result, many oral ulcerative con-
ditions, including CUS, are empirically treated without 
an accurate diagnosis (2).
Recently, a group proposed the development of En-
zyme-linked Immunosorbent Assay (ELISA) for the 
detection of IgG antibodies to the N-terminal immuno-
genic portion of DNp63a (DNp63) in a cohort of CUS 
sera (8). However, the lack of a greater number of posi-
tive controls was an important limitation in this study. 
Therefore, future studies are needed to better under-
stand these findings.
The results of this systematic review showed that severe 
cases of CUS seem to be controlled with the use of hy-
droxychloroquine sulfate (1,2,4,11,13,14,16,17,22). Im-
portant to notice, hydroxychloroquine must be carefully 
administered due to its side effects, such as retinopathy, 
toxic psychosis, neuropathy, agranulocytosis, and aplas-
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tic anemia, which may lead to treatment discontinuation 
(13). Neuromuscular and hematologic complications are 
usually reversible, whereas retinal are not. In this man-
ner, close follow-up of patients who take hydroxychlo-
roquine is required (12). Alternatively, chloroquanidine, 
which has a high therapeutic index and appears to be 
well tolerated, may become the drug of choice to treat 
this condition. Furthermore, less severe cases can be 
controlled by selected topical corticosteroids, although 
lesions tend to recur (1,2,4,11,12,14,18). 
Interestingly, in an analysis of 42 OLP cases, derived 
from a previous published single-center, randomized, 
controlled, single-blind study, which had different re-
sponses to two types of treatment (topical corticoste-
roid or laser phototherapy), high levels of acetyl-histone 
H3 at lys9 (H3K9ac) were intrinsic related to failure in 
responding to the proposed treatment or to disease re-
currence shortly after therapy. Furthermore, presence 
of DNA double-strand breaks (DSBs), demonstrated by 
accumulation of γH2AX histones, were also found in 
those highlighted cases, indicating genomic instability 
and poor response to treatment (23). Since OLP is simi-
lar to other oral immunological disorders, as CUS, it 
would be possible that these histones modifications, if 
found in CUS cases, could explain the disorder’s inad-
equate response to corticosteroid therapy.
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